FAQ: Lantern Pharma's FDA Guidance and Pediatric Cancer Therapy Development
Summary
Lantern Pharma received FDA guidance for its LP-184/STAR-001 therapy targeting rare pediatric brain cancers, setting the stage for a planned Q1 2026 clinical trial launch. This regulatory progress represents a significant step forward in addressing unmet medical needs in pediatric oncology while the company also reported complete responses in two current trials.
What is the main focus of Lantern Pharma’s recent FDA meeting?
Lantern Pharma’s Type C meeting with the FDA provided guidance on the regulatory pathway and trial design for its investigational therapy LP-184/STAR-001, which targets pediatric central nervous system cancers including Atypical Teratoid Rhabdoid Tumor (ATRT).
When does Lantern Pharma plan to launch its pediatric cancer trial?
The company plans to launch its clinical trial for LP-184/STAR-001 in Q1 of 2026, following amendments to its investigational new drug (IND) submission based on FDA guidance.
What types of cancers is Lantern Pharma targeting with its drug candidates?
Beyond pediatric brain cancers, Lantern Pharma is developing therapies for glioblastoma (GBM), triple-negative breast cancer, non-small cell lung cancer in non-smokers, non-Hodgkin’s lymphoma, and other tumors with unmet medical needs.
How does Lantern Pharma develop its cancer therapies?
The company uses its proprietary drug candidates combined with a computational biology and machine learning platform to develop targeted therapies for conditions with significant unmet medical needs.
What recent clinical successes has Lantern Pharma reported?
During the past quarter, two of the company’s current trials achieved complete responses in patients, indicating positive treatment outcomes in their ongoing clinical development programs.
Where can investors find the latest updates about Lantern Pharma?
The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN, as noted in the investor information section of the content.
What is LP-184/STAR-001 and what does it target?
LP-184/STAR-001 is Lantern Pharma’s investigational therapy designed to combat pediatric central nervous system cancers, specifically targeting rare conditions like Atypical Teratoid Rhabdoid Tumor (ATRT) and other pediatric brain cancers.
Why is this FDA guidance significant for Lantern Pharma?
The FDA guidance provides critical regulatory direction that helps Lantern Pharma refine its trial design and navigate the approval pathway, accelerating progress toward clinical trial initiation and potential treatment development for rare pediatric cancers.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 239669